Stockscreener 앱 받기
1.69
6.29%
0.10
시간 외 거래:
1.77
0.08
+4.73%
Immix Biopharma Inc 주식(IMMX)의 최신 뉴스
Private Advisor Group LLC Has $51,000 Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201 - CGTLive™
Immix BiopharmaUS CAR-T trial progresses to dose expansion - Smartkarma
H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing.com
Immix Biopharma’s (IMMX) “Buy” Rating Reiterated at HC Wainwright - Defense World
XTX Topco Ltd Sells 34,534 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort - GlobeNewswire
Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - StockTitan
Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com Australia
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, - GlobeNewswire
Immix Biopharma gains AL Amyloidosis expert for advisory board - Investing.com
Immix Biopharma gains AL Amyloidosis expert for advisory board By Investing.com - Investing.com Australia
Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - StockTitan
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat
It would be worthwhile to take a closer look at Immix Biopharma Inc (IMMX) - US Post News
Its Stock Has Paid Off Big Time For Immix Biopharma Inc - SETE News
The Attractiveness of Investing In Immix Biopharma Inc (IMMX) is Growing - Knox Daily
Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance UK
Insider Spends US$52k Buying More Shares In Immix Biopharma - Simply Wall St
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy - Investing.com
Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy By Investing.com - Investing.com Canada
Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewswire
The markets will rise or fall with NVDA - RagingBull
Immix Biopharma director Jason Hsu buys $51,623 in company stock - Investing.com
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Immix Biopharma Inc’s latest rating changes from various analysts - Knox Daily
Q3 2024 Earnings Estimate for Immix Biopharma, Inc. Issued By HC Wainwright (NASDAQ:IMMX) - MarketBeat
HC Wainwright Weighs in on Immix Biopharma, Inc.’s Q3 2024 Earnings (NASDAQ:IMMX) - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng Purchases 10,000 Shares of Stock - Defense World
Immix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in Stock - MarketBeat
Immix Biopharma, Inc. to Post FY2024 Earnings of ($0.61) Per Share, Edison Inv. Res Forecasts (NASDAQ:IMMX) - MarketBeat
Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.5% in July - MarketBeat
What Makes Immix Biopharma (IMMX) a New Buy Stock - MSN
Immix Biopharma (NASDAQ:IMMX) Rating Reiterated by HC Wainwright - MarketBeat
HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World
FY2024 Earnings Forecast for Immix Biopharma, Inc. (NASDAQ:IMMX) Issued By Edison Inv. Res - Defense World
IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 - InvestorPlace
Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St
Monitoring Immix Biopharma Inc (IMMX) after recent insider movements - Knox Daily
Jason Hsu Purchases 6,000 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) Stock - Defense World
Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies - CGTLive™
Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com
3.66%
1.11%
자본화:
|
볼륨(24시간):